TMEM229A

Across TCGA pan-cancer cohorts, TMEM229A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TMEM229A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TMEM229A RNA is repressed in tumor relative to normal tissue. In most cancer types TMEM229A is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and BLCA are the cancer types where TMEM229A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM229A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	−0.282	<.001	11	view →
KIRC	All	All	−0.084	<.001	10	view →
BLCA	Male	IV	−1.775	.001	8	view →
UCEC	All	II,III,IV	−0.837	<.001	8	view →
HNSC	All	All	−0.141	.001	8	view →
KICH	All	All	−0.118	<.001	8	view →
READ	All	II,III,IV	−0.185	.014	3	view →
PRAD	All	All	−0.290	<.001	2	view →
KIRP	All	All	−0.078	<.001	2	view →
STAD	Male	IV	−0.845	.023	1	view →
LUAD	All	All	+0.350	.010	1	view →
COAD	All	All	−0.303	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TMEM229A–THCA

Open the THCA breakdown →